Table S1 Inclusion and exclusion criteria

Inclusion criteria	Exclusion criteria
Provisional enrollment (at screening)	
Written informed consent before starting the study	Stress urinary incontinence
Patient was ≥20 years of age at the time of informed consent. Female patients had to be an outpatient with OAB who had been postmenopausal for ≥1 year. Male patients had to be an outpatient with OAB who did not wish to have children in the future	Transient symptoms suggestive of OAB
Previously treated with MIRA at a stable dose of 50 mg once daily for ≥6 weeks before the start of the screening period	Urinary tract infection, urinary calculus, or interstitial cystitis, or a history of recurrent urinary tract infection (≥3 episodes within 24 weeks before the start of the screening period)
Capable of walking to the bathroom without assistance	Bladder or prostate tumor or a medical history of these type of tumors
OABSS total score of ≥3 points and an OABSS question 3 score of ≥2 points	PVR volume of ≥100 mL or had benign prostatic hyperplasia or lower urinary tract obstruction
	Uncontrolled hypertension (SBP of ≥180 mmHg or DBP of ≥110 mmHg measured in a sitting position)
	Pulse rate of ≥110 b.p.m. or <50 b.p.m.
	Contraindication to antimuscarinics
	Glaucoma, ulcerative colitis, hyperthyroidism, dementia, cognitive dysfunction, parkinsonism symptoms, or a clinically significant cerebrovascular disorder
	Serious heart disease, liver disease, kidney disease, immunological disease, lung disease, etc., or a previous malignant tumor (except patients who had not received treatment for a malignant tumor for ≥5 years before the start of the screening period and were not considered to be at risk of recurrence)
	Known hypersensitivity to β-agonists or antimuscarinics
	Receiving treatment with flecainide acetate or propafenone hydrochloride
	Long QT syndrome; vulnerable to an arrhythmia, such as bradycardia or acute myocardial ischemia; hypokalemia; or ischemic heart disease, such as angina pectoris
	Used any prohibited concomitant medication within 4 weeks before the start of the screening period

Inclusion criteria	Exclusion criteria
	Receiving catheterization or intermittent self-catheterization or had pelvic organ prolapse that affected urinary tract function
	Received radiotherapy that affected urinary tract function
	Received surgical therapy that may have affected urinary tract functioning within 24 weeks before the start of the screening period
	Received non-pharmacological therapy for OAB such as electric stimulation therapy, biofeedback therapy, bladder training, or pelvic floor muscle exercise training within 2 weeks before the start of the screening period
	Diagnosed with a mood disorder, a neurotic disorder, or schizophrenia, or had a history of these diseases
	Participated in any clinical trial or post-marketing clinical study, involving other ethical drugs or medical equipment, within 12 weeks before the start of the screening period or was currently participating in this type of study
	Judged to be unsuitable for the study by the investigator
Final enrollment (at randomization)	
OABSS total score of ≥3 points and an OABSS question 3 score of ≥2 points	Polyuria with a mean daily urine volume of >3000 mL (confirmed using the micturition diary during the screening period)
	PVR volume of ≥100 mL or had benign prostatic hyperplasia or lower urinary tract obstruction
	Uncontrolled hypertension (SBP of ≥180 mmHg or DBP of ≥110 mmHg measured in a sitting position)
	Pulse rate of ≥110 b.p.m. or <50 b.p.m.
	Any of the following after examination of the screening visit results: an abnormal ECG that precluded participation or a QTcF of ≥450 ms, AST or ALT of ≥100 IU/L, or creatinine of ≥2.0 mg/dL
	Satisfied any of the screening exclusion criteria
	Not eligible for the study in the opinion of the investigator

ALT, alanine aminotransferase; AST, aspartate aminotransferase; DBP, diastolic blood pressure; ECG, electrocardiogram; MIRA, mirabegron; OAB, overactive bladder; OABSS, overactive bladder symptom score; PVR, post-void residual; QTcF, QT interval corrected for heart rate by Fridericia's formula; SBP, systolic blood pressure.